Tau modifiers as therapeutic targets for Alzheimer's disease

Quan Liu, Hyoung Gon Lee, Kazuhiro Honda, Sandra L. Siedlak, Peggy L.R. Harris, Adam D. Cash, Xiongwei Zhu, Jesús Avila, Akihiko Nunomura, Atsushi Takeda, Mark A. Smith, George Perry

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Fibrillogenesis is a major feature of Alzheimer's disease (AD) and other neurodegenerative diseases. Fibers are correlated with disease severity and they have been implicated as playing a direct role in disease pathophysiology. In studies of tau, instead of finding causality with tau fibrils, we found that tau is associated with reduction of oxidative stress. Biochemical findings show that tau oxidative modifications are regulated by phosphorylation and that tau found in neurofibrillary tangles is oxidatively modified, suggesting that tau is closely linked to the biology, not toxicity, of AD.

Original languageEnglish
Pages (from-to)211-215
Number of pages5
JournalBiochimica et Biophysica Acta - Molecular Basis of Disease
Volume1739
Issue number2
DOIs
Publication statusPublished - 2005 Jan 3

Keywords

  • 4-hydroxy-2-nonenal
  • Alzheimer's disease
  • Heme oxygenase
  • Lipid peroxidation
  • Oxidative stress

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology

Fingerprint Dive into the research topics of 'Tau modifiers as therapeutic targets for Alzheimer's disease'. Together they form a unique fingerprint.

  • Cite this

    Liu, Q., Lee, H. G., Honda, K., Siedlak, S. L., Harris, P. L. R., Cash, A. D., Zhu, X., Avila, J., Nunomura, A., Takeda, A., Smith, M. A., & Perry, G. (2005). Tau modifiers as therapeutic targets for Alzheimer's disease. Biochimica et Biophysica Acta - Molecular Basis of Disease, 1739(2), 211-215. https://doi.org/10.1016/j.bbadis.2004.06.021